# A Observational Study to Evaluate Deucravacitinib in Patients With Moderate Plaque Psoriasis in China

> **NCT06512337** · — · ACTIVE_NOT_RECRUITING · sponsor: **Bristol-Myers Squibb** · enrollment: 153 (actual)

## Conditions studied

- Plaque Psoriasis

## Interventions

- **DRUG:** Deucravacitinib

## Key facts

- **NCT ID:** NCT06512337
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-01-20
- **Primary completion:** 2027-03-11
- **Final completion:** 2027-03-11
- **Target enrollment:** 153 (ACTUAL)
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06512337

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06512337, "A Observational Study to Evaluate Deucravacitinib in Patients With Moderate Plaque Psoriasis in China". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06512337. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*